Literature DB >> 1853915

The prevalence of autoantibodies during third-trimester pregnancy complicated by hypertension or idiopathic fetal growth retardation.

J Milliez1, F Lelong, N Bayani, D Jannet, M el Medjadji, H Latrous, M Hammami, B J Paniel.   

Abstract

Lupus anticoagulant, anticardiolipin, antinuclear, anti-deoxyribonucleic acid, antithyroglobulin, and antithyroid microsomal antibodies were assayed during third-trimester pregnancy (100 normal, 100 with complications). In spite of a normal activated partial thromboplastin time in all instances, lupus anticoagulant was further investigated by three additional procedures: tissue thromboplastin inhibition time, platelet neutralization procedure, and cephalin neutralization test. The prevalence of autoantibodies in pregnancies with hypertension reaches 16% (four with lupus anticoagulant, two with anticardiolipin, and two with antithyroid microsomal antibodies), which is significantly greater than that for idiopathic fetal growth retardation (2%) (one with lupus anticoagulant antibodies) and normal pregnancies (3%) (two with antithyroglobulin and one with autithyroid microsomal antibodies) (p less than 0.01). Autoantibodies were equally distributed between patients with gestational hypertension and those with preeclampsia. When compared with the 42 patients with hypertension and no autoantibodies, the eight patients with autoantibody had a more frequent history of fetal growth retardation (p less than 0.05), but there was no difference in the severity of hypertension, the frequency of obstetric complications, or the outcome of pregnancy. They did not require any specific treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1853915     DOI: 10.1016/0002-9378(91)90222-d

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy.

Authors:  Karoline Mayer-Pickel; Katharina Eberhard; Uwe Lang; Mila Cervar-Zivkovic
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

3.  Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study.

Authors:  K J Gibbins; A E Tebo; S K Nielsen; D W Branch
Journal:  Lupus       Date:  2018-07-20       Impact factor: 2.911

Review 4.  Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications.

Authors:  A M Lynch; J E Salmon
Journal:  Placenta       Date:  2010-04-27       Impact factor: 3.481

Review 5.  Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?

Authors:  Guilherme R de Jesús; Gustavo Rodrigues; Nilson R de Jesús; Roger A Levy
Journal:  Curr Rheumatol Rep       Date:  2014-02       Impact factor: 4.592

Review 6.  Antiphospholipid Antibodies Increase the Risk of Fetal Growth Restriction: A Systematic Meta-Analysis.

Authors:  Jinfeng Xu; Daijuan Chen; Yuan Tian; Xiaodong Wang; Bing Peng
Journal:  Int J Clin Pract       Date:  2022-01-31       Impact factor: 3.149

Review 7.  Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?

Authors:  Erin A S Clark; Robert M Silver; D Ware Branch
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.